Here's How Intrexon Might Prove Me Wrong
I've been quick to point out when marketing hype doesn't match up with what's realistically possible from a technical standpoint. Unfortunately, in my opinion, there have been many such instances in the early stages of the industrial biotech industry.
That's why I've strongly argued that investors should temper expectations regarding the natural-gas-to-chemicals technology platform being developed by engineered biology conglomerate Intrexon (NYSE: XON).
But science is often about having an open mind. At the end of July, I traveled to the BIO World Congress on Industrial Biotechnology in Montreal, where I caught up with Intrexon Energy Senior Vice President Bob Walsh. We discussed the novel technology platform under development and why Intrexon thinks it's going to prove me wrong.
Source: Fool.com
Equinor ASA ADR Aktie
Noch unklar: Equinor ASA ADR hat nur wenige Buy- und Sell-Einschätzungen.
Für Equinor ASA ADR sieht die Community ein Kursziel von 38 €, was eine erhebliche Steigerung um über 50% gegenüber dem aktuellen Kurs von 24.0 € bedeutet.
